We describe the durable correction of streptozotocin-induced murine diabetes by in vivo implantation of primary mouse hepatocytes electroporated ex vivo with a human proinsulin cDNA plasmid construct controlled by glucose and zinc regulatory elements. Transfected hepatocytes increased insulin transgene transcription and secretion within 10-20 min of exposure to 25 mM glucose or 60 mM zinc. Insulin release did not occur from secretory granules. Electroporated Rosa26 hepatocytes (B8 Â 10 5 viable cells) were implanted in C57BL/6J diabetic mice in one of three sites: unresected liver, regenerating liver or mesentery. Control diabetic mice were implanted with untransfected hepatocytes. At 30 days after implantation, 8/15 control mice were alive, while 19/19 treated mice were alive. The ratio of body weight on day 30/nadir body weight was significantly higher for all treated groups compared with controls. All eight surviving control mice were hyperglycemic 30 days postimplantation, while 16/19 treated diabetic mice remained normoglycemic. Treated mice had lower mean glucose values (Pp0.001) without fasting hypoglycemia and better glucose tolerance (Pp0.0003) than untreated controls. All (6/6) diabetic mice implanted in regenerating liver and 71% (5/7) implanted in unresected liver were alive 77 days after implantation. Engrafted hepatocytes were identified, mainly around central veins, by staining for b-galactosidase activity and with anti-human insulin antibody. Gene Therapy (2005) 12, 655-667.
Introduction
The current range of clinically approved treatments for diabetes mellitus often fails to achieve sustained and good glycemic control. Approaches for restoring insulin secretion by gene-based therapies have achieved proof of concept in murine diabetes in recent years. These strategies were directed mainly at developing viral vectors for in vivo delivery of insulin transgenes to potential surrogate b cells such as hepatocytes, 1,2 at modifying cell lines 3 or primary cells 4 ex vivo. None, however, has yet entered clinical trials, largely because of reservations regarding the biosafety of adeno-and retroviral vectors 5, 6 and inability to replicate physiological insulin expression and secretion in non-b cells, with fatal hypoglycemia being a frequent complication.
Cell-based treatment is an alternative to gene-based therapy. Allogeneic islet transplantation for type I diabetes is clinically successful in specialized centres, but will have only limited overall impact on diabetes care owing to the scarcity of islet donors. Most cell-based approaches at present use engineered cell lines 3 or attempt to differentiate embryonic or adult stem/ progenitor cells into islets, 7 although culture conditions that favour differentiation of stem cells to b cells are largely unknown and empirical. Others have reported transdifferentiation of hepatocytes into insulin-producing cells by forced overexpression of pancreatic transcription factors. 8, 9 In contrast, much less has been achieved in modifying primary adult somatic cells for physiological insulin secretion. This is a worthwhile goal because it could pave the way for autologous cell-based therapy of diabetes and other metabolic disorders.
We have modified primary hepatocytes ex vivo for insulin secretion and implanted them into diabetic mice in vivo. Mature hepatocytes resemble b cells in their capacity for glucose sensing and glucose-regulated transcription, but are regarded as imperfect surrogates for physiological b-cell function because they lack a regulated secretory pathway. 10 Our study is the first to show that primary adult hepatocytes can be genetically modified to secrete insulin with rapid kinetics in response to high extracellular glucose concentrations. The gene vector in this study was an expression plasmid that placed human proinsulin cDNA, modified for furin cleavage and encoding the HisB10Asp variant, 11 under the control of a bifunctional promoter 12 comprising the human metallothionein IIA promoter and a single copy of the carbohydrate response element (ChoRE) from the L-type pyruvate kinase (LPK) gene. While all other studies to date have used viral vectors, calcium phosphate or liposomes to deliver insulin transgenes into cells, we have achieved efficient transgene delivery into primary hepatocytes by electroporation. The plasmid-electroporated primary hepatocytes engrafted after in vivo implantation in streptozotocin (STZ)-diabetic mice, secreted human insulin, restored euglycemia and body weight. Glucose tolerance and survival improved in treated mice.
Results

Electroporation of primary hepatocytes
Transfection of primary hepatocytes was accomplished using the Amaxa Nucleofectort system. In the absence of a protocol for primary mouse hepatocytes, we initially used the manufacturer's optimization guide and a reporter plasmid expressing green fluorescent protein (pEGFP). The preset programs T28, T20 and H22 resulted in transfection efficiencies of 30-35, 25-30 and 20-25%, respectively. However, they had different effects on cell viability. H22 was associated with highest viability (85-95%), T20 with intermediate viability (60-70%), while viability after T28 electroporation was poorest (40-50%).
Electroporation optimized for insulin transgene
Cells undergoing mitosis may be more permissive for uptake and nuclear transfer of plasmid DNA. To test this hypothesis, we isolated hepatocytes from unresected liver and from livers 24 and 48 h after partial hepatectomy (PH). Primary hepatocytes obtained under each of these conditions were transfected with pEGFP using different Amaxa electroporation programs, T20, T28 and H22. Transfection efficiency doubled to 40-50% with 80-90% viability using program H22 on hepatocytes isolated 24 h after PH. The same approach was then adopted for transfection of the insulin transgene. To evaluate cellular damage induced by different electroporation programs, L-alanine: 2-oxoglutarate aminotransferase (ALT) activity was assayed in culture media withdrawn 6 h after plating electroporated hepatocytes. Figure 1 shows human insulin concentrations in 48 h conditioned media under different conditions of hepatocyte isolation (from unresected liver, from liver regenerating 24 and 48 h after PH) and electroporation (T20, T28 and H22 programs). Hepatocytes isolated from liver 24 and 48 h after PH secreted significantly more insulin (198.476.6 and 186.0734.4 pM, respectively; mean7 s.e.m.) than hepatocytes isolated from unresected liver (43.072.0 pM) (Po0.0001 and o0.002, respectively). However, within each group of hepatocytes, comparable insulin secretion was obtained with all three electroporation programs tested. We noted that using program H22 on hepatocytes isolated 24 h after PH caused least cellular injury as judged by significantly lower ALT activity in the conditioned media (H22: 2.870.08 U/l; T20: 3.6370.15 U/l; T28: 3.7570.11 U/l; mean7s.e.m.; Po0.05 for the difference between H22 and T20, and between H22 and T28).
Processing and secretion of mature human insulin by hepatocytes
The human proinsulin cDNA in this study, p3MTChins, was modified to introduce furin-cleavable sites 4 and the HisB10Asp substitution that is known to enhance biopotency. 11 To confirm proinsulin processing by hepatocytes and to determine if processing was influenced by different cell attachment matrices, we electroporated 10 6 primary mouse hepatocytes with p3MTChins and cultured the cells on rat tail collagen I, mouse collagen IV or Matrigel s . Conditioned media were assayed for human insulin and proinsulin 24, 48 and 72 h after plating. The mature form of human insulin was the major secretory product on all matrices (490%). Taking the sum of the molar concentrations of human insulin and proinsulin in the conditioned media to be 100%, the molar concentration of human proinsulin was 2.271.4% on collagen I, 3.271.9% on collagen IV and 8.772.3% on Matrigel s (mean7s.e.m.; n ¼ 3). Proinsulin concentration relative to mature insulin was significantly higher in Matrigel s conditioned media compared to collagen I and IV (P ¼ 0.0091 and 0.0424, respectively). Hepatocytes were plated on collagen I in all subsequent experiments, as this was most favorable for proinsulin processing.
Static induction of human insulin by glucose and zinc in vitro
The response of the bifunctional promoter to increasing glucose or zinc concentrations was tested in hepatocytes electroporated with p3MTChins. Figure 2a shows that the threshold glucose concentration for stimulated insulin secretion was 2.5 mM (P ¼ 0.0039 compared to insulin secretion at 1 mM glucose), and that maximal stimulated secretion had not occurred at 25 mM glucose (P ¼ 0.0002 compared to insulin secretion at 15 mM glucose). The threshold zinc concentration for stimulated insulin secretion was between 10 and 15 mM (P ¼ 0.065 and 0.0014, respectively, compared to zinc-free medium). Like glucose stimulation, all higher zinc concentrations tested (20-60 mM) continued to further induce highly significant increases in insulin secretion (Po0.001). Thus, there was no evidence that the maximum capacity for stimulated insulin secretion had been reached at the highest concentrations of glucose (25 mM) and zinc (60 mM) tested when insulin concentrations in the conditioned media had increased 4.2-and 5-fold, respectively. 6 cells isolated from Rosa26 liver 24 and 48 h after 30% PH were electroporated with 5 mg p3MTChins in an equal mixture of Nucleofectort #3551 and #3541 solutions using different preset Amaxa programs (T20, T28 and H22). Human insulin and ALT activity were assayed in conditioned media 48 and 6 h, respectively, after plating. Control cells were mock transfected (electroporated using programs T28 and H22 in the absence of plasmid). Data are mean7s.e.m. Significantly different from unresected liver, *Po0.0001, **P ¼ 0.002 (n ¼ 6).
Hepatocyte-mediated therapy of murine diabetes NKF Chen et al Figure 2 (a) Glucose-and zinc-induced insulin secretion. Primary mouse hepatocytes transfected with p3MTChins as described in Materials and methods were plated in collagen-coated 35 mm dishes with 25 mM glucose DMEM (10 6 cells/well). The medium was changed after 5 h and replaced with fresh DMEM containing increasing glucose (1, 2.5, 4, 7, 10, 15 and 25 mM) or zinc (0, 5, 10, 15, 20 and 60 mM) concentrations. Conditioned media (24-h) were assayed in duplicate for human insulin. Data are the mean and s.e.m. values of three separate experiments. Insulin concentrations were significantly higher when glucose concentration increased from 1 to 2.5 mM (P ¼ 0.0039) and from 15 to 25 mM (P ¼ 0.0002), as well as at intermediate glucose concentrations. Compared to zinc-free medium, insulin concentrations were higher when zinc concentration was 10 mM (P ¼ 0.065) and 15 mM (P ¼ 0.0014). (b) Kinetics of glucose-induced insulin secretion. 2 Â 10 6 primary mouse hepatocytes, isolated 24 h after PH, were electroporated with 5 mg p3MTChins and 3 mg pSEAP using Amaxa program H22, and cultured on a 35 mm dish coated with rat tail collagen I in zinc-free 5.6 mM glucose DMEM for 24 h. Cells were washed thrice with PBS before continuous perifusion (2 ml/min) at 371C with the following sequence of glucose concentrations in DMEM: 2.5 mM ('low glucose') Â 30 min/25 mM ('high glucose') Â 40 min/2.5 mM Â 40 min/25 mM Â 40 min/2.5 mM Â 40 min. Perfusate fractions were collected every 2 min throughout and assayed for human insulin, SEAP and ALT activity. Hepatocyte-mediated therapy of murine diabetes NKF Chen et al
Kinetics of glucose-and zinc-induced insulin secretion
In contrast to neuroendocrine cells, protein secretion by hepatocytes is generally regarded as lacking the capacity for rapid response owing to absence of a regulated secretory pathway. Thus, transcriptionally regulated insulin expression by hepatocytes from the L-PK and metallothionein promoters would be expected to exhibit slow kinetic response. However, minute-to-minute insulin-secretory response under these conditions has not been documented to date. We therefore characterized the kinetics of inducible insulin secretion by primary hepatocytes cotransfected with the bifunctional promoter construct and pSEAP expressing secreted alkaline phosphatase under the SV40 promoter in a series of perifusion experiments in which 1 Â 10 6 and 2 Â 10 6 hepatocytes cultured on 35 mm collagen I-coated dishes were stimulated by separate timed exposures to 60 mM zinc (30 min) or 25 mM glucose (40 min), respectively, in continuously flowing medium (2 ml/min). Human insulin in the perfusate rose at least 2.5-fold above baseline (defined as the mean insulin concentration during the washout period with 2.5 mM glucose zinc-free medium) for at least three consecutive time points 12 min after increasing glucose concentration in the perifusing medium from 2.5 to 25 mM (Figure 2b ). However, insulin secretion declined more slowly when the glucose stimulus was removed, reaching basal levels only after 30 min. On re-stimulation with a second exposure to 25 mM glucose, insulin secretion again rose briskly above basal levels after 10 min and declined to baseline 32 min after the glucose stimulus was withdrawn. In separate experiments, primary hepatocytes were perifused with 2.5 mM glucose Dulbecco's modified Eagle's medium (DMEM) that was either zinc-free or supplemented with 60 mM zinc. Human insulin concentration in the perfusate significantly increased above basal levels 18 min after exposure to 60 mM zinc and declined to basal levels 30 min after zinc withdrawal (Figure 2c) . A second exposure to 60 mM zinc stimulated insulin secretion after 20 min and declined to basal levels 30 min after zinc was removed.
In contrast to the inducible response of insulin secretion by high glucose or zinc concentrations, SEAP activity in the same perfusate fractions did not change in tandem with glucose or zinc exposure (Figure 2c and d) . This was consistent with the constitutive nature of the SV40 promoter in contrast to the inducible nature of our bifunctional promoter. ALT activity in the perfusate remained low and stable throughout all perifusion experiments (data not shown).
Transcriptional response of transgene
The transcriptional responsiveness of p3MTChins to glucose and zinc stimulation was next investigated to determine if the rapid responses observed in perifused hepatocytes correlated with upregulation of transgene mRNA. Data from three separate experiments are summarized in Table 1 . A human insulin cDNA construct that was identical to p3MTChins except that the CMV promoter replaced the metallothionein promoter and ChoRE was used as a nonresponder control. Insulin mRNA levels showed a clear increase (1.27-2.44-fold) over baseline 6-10 min after addition of 25 mM glucose ( Table 1 , Experiments A and B) and declined by 20 min after glucose withdrawal, concordant with perifusion data of Figure 2b . Likewise, insulin mRNA levels rose 1.26-1.85-fold above baseline 6-10 min after addition of 60 mM zinc (Table 1, Experiment C) and declined to baseline 20-40 min after zinc withdrawal. In contrast, insulin mRNA expressed from the CMV promoter (pCMVIns) did not show consistent upregulation to either glucose or zinc.
Implantation of transfected primary hepatocytes into diabetic mice
We next implanted transfected primary Rosa26 mouse hepatocytes into STZ-diabetic C57BL6 mice. Donor RNA was isolated from primary C57BL/6J hepatocytes transfected with p3MTChins (metallothionein promoter and carbohydrate response element) or pCMVIns (CMV promoter) before addition of 25 mM glucose or 60 mM zinc, 3, 6, 10 and 15 min after addition of glucose or zinc; and 20 and 40 min after glucose or zinc withdrawal. Semiquantitative RT-PCR was performed as detailed in 'Materials and methods' using SYBR s Green for PCR product detection. Data were analyzed using the Opticon Monitort Analysis software, version 1.07 (MJ Research, USA). Differences in RNA input for reverse transcription were normalized using C t values obtained in parallel for mouse HPRT mRNA. The ratio of mRNA at each time point after induction/mRNA before induction was given by the equation 2 (bÀy) [2
, where a is the C t value of the uninduced sample and x is the C t value of an induced sample, b and y are, respectively, the minus reverse transcriptase controls for a and x. Time points after addition of glucose or zinc are denoted by + and time points after withdrawal of the stimulus by À.
Hepatocyte-mediated therapy of murine diabetes NKF Chen et al hepatocytes were prepared from unresected liver because the proliferative capacity of hepatocytes from regenerating liver would likely lead to loss of transfected plasmids. The in vivo study was divided into three separate experiments of identical design. Three different hepatocyte implantation sites were investigated in each experiment: right lateral and right medial lobes of unresected liver (group 1; n ¼ 7), the same lobes of partially hepatectomized liver (group 2; n ¼ 6) and abdominal mesentery (group 3; n ¼ 6). Viable hepatocytes (8 Â 10 5 after electroporation) were implanted by direct interstitial injection through a 29 G needle in all sites. Control diabetic mice were implanted with the same number of untransfected primary hepatocytes at the same sites (mock implanted).
The outcome of hepatocyte implantation was assessed by (a) survival; (b) serial body weights; (c) blood glucose concentrations; (d) glucose tolerance; (e) plasma human insulin and (f) plasma mouse C-peptide levels. (a) Survival: At 30 days after implantation with untransfected hepatocytes, 8/15 (53%) of control diabetic mice were alive compared with 19/19 (100%) of diabetic mice implanted with hepatocytes electroporated with p3MTChins. At 77 days after implantation, 2/15 (13.3%) control diabetic mice were alive, while 12/19 (63.2%) treated diabetic mice were alive ( Figure 3a ). Among the treated diabetic mice, cellular implantation in the liver was associated with superior survival compared to mesenteric implantation. At 77 days after implantation, all group 2 diabetic mice were alive (6/6; 100%) as were most group 1 diabetic mice (5/7, 71.4%) compared to only 16.7% mesenteric-implanted mice (1/6, group 3). (b) Body weights: Weight loss was recorded in all diabetic mice (34/34). However, all mice implanted with transfected cells (19/19) began to gain weight after the third post-operative day, whereas none of the control diabetic mice implanted with untransfected hepatocytes (0/15) regained their original body weights ( Figure 3b ). Weight gain was greatest in group 2 mice whose mean body weight was significantly higher than all other groups from the 10th post-implantation day onwards. Their mean body weight gain was 1.46 g higher than group 1 mice (P ¼ 0.05) by day 30. Given that whole adult mouse liver weighed about 1.2 g, the increase in body weight among group 2 mice could not be ascribed entirely to liver regeneration. Among survivors, the ratio of day 30 body weight/nadir body weight (1.42 for group 2; 1.31 for group 1; 1.18 for group 3 and 1.07 for control mice implanted in all sites) was significantly higher for all treated groups (Po0.0001, o0.0001 and 0.0445, respectively) compared with control diabetic mice. (c) Blood glucose: Regardless of implantation site, all diabetic mice implanted with electroporated hepatocytes (19/19) became normoglycemic 24 h after implantation (Figure 3c ). Blood glucose of group 2 mice (n ¼ 6) showed the steepest decline (mean7s.e.m.: 27.776.3 to 6.271.9 mM; À78%), followed by group 1 (n ¼ 7) (24.872.7 to 8.671.3 mM; À65%) and group 3 (n ¼ 6) (30.876.7 to 11.472.2 mM; À63%). In contrast, all control diabetic mice (n ¼ 15) implanted with untransfected hepatocytes became more hyperglycemic (25.974.5 to 28.675.4 mM; +10%). At 30 days post-implantation, all eight surviving control diabetic mice remained hyperglycemic, while 16/19 (84%) treated diabetic mice remained normoglycemic. The only three mice of 19 treated diabetic mice that reverted to hyperglycemia by day 30 were all implanted in the mesentery, consistent with this implantation site being least effective. The means of six nonfasting blood glucose concentrations determined at intervals over the 30-day period after implantation were 9.270.6 mM (group 2), 10.370.8 mM (group 1) and 12.972.2 mM (group 3). All were significantly lower (Po0.001) than diabetic mice implanted with untransfected hepatocytes (25.972.7 mM). At no time were blood glucose levels o3.8 mM recorded among treated mice. Although there was a slight rising trend, mean blood glucose levels on days 3 and 30 after hepatocyte implantation were not significantly different in any of the treated groups. Blood glucose concentrations on the third post-implant day (group 1 (9.470.5 mM), 2 (8.170.6 mM) and 3 (11.770.9 mM)) were not significantly different from values obtained on the 30th post-implant day (group 1 (10.370.5 mM), 2 (10.370.9 mM) and 3 (15.572.1 mM)) (P ¼ 0.2309, 0.0663 and 0.0851 for groups 1, 2 and 3, respectively)). (d) Glucose tolerance to an intraperitoneal load (1.5 mg glucose/g body weight) administered 30 days after hepatocyte implantation is shown in Figure 3d . Using the area under the curve (AUC) as a measure of glucose tolerance, implantation of transfected hepatocytes at all three sites significantly improved glucose tolerance (Po0.0001 for liver implantation; P ¼ 0.0051 for mesenteric implantation) compared to control diabetic mice. AUC was not significantly different for hepatocytes implantated into unresected and regenerating liver. Plasma human insulin levels in these groups were also not different (unresected liver 113.2715.1 pM (mean7s.e.m.); regenerating liver 133.0715.5 pM; two-tailed P-value ¼ 0.3812). However, glucose tolerance in mesenteric-implanted diabetic mice was significantly worse than both liver-implanted groups (Po0.02). None of the mice was hypoglycemic after a 16-18 h fast at the commencement of glucose tolerance testing. (e) Plasma human insulin: Human insulin peaked in the plasma of all treated groups 24 h after implantation with transfected hepatocytes, the highest concentration being in group 2 (4777165 pM; n ¼ 6), the lowest in group 3 (62716 pM; n ¼ 6), while group 1 was intermediate (190791 pM; n ¼ 7) (Figure 3e ). However, plasma human insulin concentrations significantly declined in all groups by the third day after implantation, because normoglycemia had been restored and a proportion of implanted hepatocytes may have failed to engraft. Nonetheless, within each treated group, plasma concentrations of human insulin 30 days after implantation were not significantly lower than day 3 levels (P ¼ 0.3849, 0.0811 and 0.0635 for groups 1, 2 and 3, respectively). (f) Plasma mouse C-peptide: Concurrent assays of plasma mouse C-peptide levels monitored endogenous insulin secretion and served as an index of islet regeneration of recipient mice after STZ treatment. Mean mouse C-peptide concentration before STZ administration was 5917151 pM (n ¼ 34), declining by 86% to 81738 pM after the STZ regimen, consistent with islet destruction (Figure 3f ). Circulating C-peptide levels on the day of hepatocyte implantation and 30 days postimplantation were not significantly different (P ¼ 0.0972, 0.5016 and 0.0706 for groups 1, 2 and 3, respectively), indicating that no significant islet regeneration had occurred.
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Glucose-induced insulin secretion in vivo
We investigated the temporal profile of human insulin secretion from transfected hepatocytes into the circulation of diabetic mice after a glucose stimulus administered as a bolus of intravenous glucose (1.5 mg/g body weight). Table 2 shows that mean plasma insulin concentrations increased by 17.8% over the unstimulated state 10 min after intravenous glucose and continued to Figure 3 (a) Survival of mock-implanted and -treated diabetic mice. Kaplan-Meier curves are shown for mock-implanted diabetic mice, diabetic mice implanted with transfected hepatocytes in regenerating liver, unresected liver and mesentery. (b) Body weight changes in mock-implanted and -treated diabetic mice. Changes in body weight during the experimental period relative to body weights immediately before STZ administration (day À5) are shown on the y-axis. Four daily injections of STZ (i.p. 100 mg/kg body weight) were administered (days À5 to À2). 8 Â 10 5 hepatocytes were implanted on day 0. Body weight changes of control diabetic mice implanted with untransfected hepatocytes at all three sites were pooled (mock implanted). Data are mean7s.e.m. Significantly different from mock-implanted diabetic mice, *P ¼ 0.0028 , **P ¼ 0.0010; not significantly different, ***P ¼ 0.1213. (c) Glycemic profiles of mock-implanted and -treated diabetic mice. Serial blood glucose concentrations were determined during the experimental period as described in the legend to (a). Data are mean7s.e.m. The dashed line is the diagnostic threshold for hyperglycemia, that is, 5 s.d.'s above the mean blood glucose of all mice before the experiment commenced. The mean blood glucose values during days 1 to 30 for all treated diabetic mice were significantly lower than mock-implanted diabetic mice (Po0.001). Blood glucose values on the third and 30th days after implantation were not significantly different for all groups, *P ¼ 0.2309, **P ¼ 0.0663, ***P ¼ 0.1212, ****P ¼ 0.5120. (d) Glucose tolerance of mock-implanted and -treated diabetic mice. Glucose (i.p. 1.5 mg/g body weight) was administered after an overnight fast to diabetic mice 30 days after implantation with transfected or untransfected hepatocytes, and to control unimplanted nondiabetic mice of the same age and sex. Blood glucose levels were determined at 0, 30, 60, 120 and 180 min. Using the AUC, glucose tolerance was significantly improved in all groups of treated diabetic mice compared to mock-implanted diabetic mice (Po0.0001 for both liver implantations; P ¼ 0.0051 for mesenteric implantation). (e) Plasma human insulin of mock-implanted and -treated diabetic mice. Serial insulin concentrations were determined in mouse plasma using a human insulin-specific RIA during the experimental period as described in the legend to (a). Human insulin was undetectable in the plasma of mock-implanted diabetic mice. Data are mean7s.e.m. The sum of all plasma human insulin levels of diabetic mice implanted with hepatocytes in regenerating liver was significantly higher than diabetic mice implanted with hepatocytes in unresected liver (P ¼ 0.0006) and mesentery (Po0.0001). The sum of all plasma insulin levels was also significantly higher in mice implanted in unresected liver compared to mesentery (Po0.0001). Plasma human insulin concentrations on the sixth and 30th days after implantation were not significantly different in all groups, *P ¼ 0.3849, **P ¼ 0.0811, ***P ¼ 0.0635. (f) Plasma mouse C-peptide of mock-implanted and -treated diabetic mice. Serial plasma C-peptide concentrations were assayed over the experimental period described in the legend to (a). Data are mean7s.e.m. Plasma C-peptide levels of treated diabetic mice 30 days after implantation were not significantly different from levels on the day of hepatocyte implantation, *P ¼ 0.0972, **P ¼ 0.5016, ***P ¼ 0.0706. Mean plasma C-peptide level on day 30 of mock-implanted diabetic mice**** was significantly higher than that on the day of implantation (P ¼ 0.0111).
Hepatocyte-mediated therapy of murine diabetes NKF Chen et al rise for up to 30 min. Thus, the brisk response in vivo was comparable in onset to the kinetics of insulin secretion observed in vitro (Figure 2b ). An identical volume of saline administered to the same mice in fact decreased mean plasma insulin concentration at 10 min. The slight rise (12.1%) 30 min after intravenous saline injection may have been a stress effect of anesthesia.
To compare the different implantation sites and to ascertain the functionality of the glucose-and zincresponsive promoter in vivo, we assayed plasma human insulin responses of diabetic mice 5 days after implantation of transfected hepatocytes in unresected liver, regenerating liver and mesentery immediately before and 3 h after a glucose challenge (i.p. 1.5 mg/g body weight). Nondiabetic mice implanted with transfected hepatocytes in the same sites were also challenged with glucose for comparison. Table 3 shows that plasma human insulin increased 9.6-33.2% in diabetic mice and 36.8-73.6% in nondiabetic mice 3 h after glucose challenge. In contrast, plasma human insulin decreased by 8 and 10% in diabetic and nondiabetic mice, respectively, after placebo challenge (ie i.p. saline). These data further confirmed that the proinsulin transgene linked to a single copy of ChoRE was glucose-responsive in vivo and that insulin secretion was higher from hepatocytes implanted in liver compared to mesentery.
Immunohistochemistry
At 2 days after implantation into the right lateral and right medial lobes of partially hepatectomized nondiabetic mice, p3MTChins-transfected Rosa26 hepatocytes were distributed throughout the liver as judged by the appearance of b-galactosidase staining in every lobe. Immunohistochemical staining with anti-human insulin antibody showed donor hepatocytes engrafted in liver lobules predominantly around the central veins. All engrafted cells showed strong cytoplasmic staining for human insulin (Figure 4a-c) . Double staining for b-galactosidase activity and human insulin showed that insulin expression was not detected in recipient liver cells, but was confined to donor cells only (Figure 4e, f) .
Discussion
The liver is a good candidate tissue for expressing therapeutic transgenes, particularly to correct metabolic diseases due to specific systemic protein deficiencies.
However, primary hepatocytes are difficult to transfect efficiently in vitro, while in vivo transduction with viral vectors and implantation of cell lines entails the risk of tumour development and/or requires long-term immunosuppression. We have shown that primary hepatocytes can be transfected with much higher efficiency, typically 40-50%, using an electroporation system. Hepatocytes prepared from actively regenerating liver appear more permissive for plasmid uptake because significantly higher insulin secretion was obtained from primary hepatocytes isolated 24 and 48 h after PH. Notwithstanding the superiority of hepatocytes from regenerating liver for plasmid uptake and transgene expression, we chose hepatocytes prepared from unresected liver for implantation in vivo in order to avoid loss of plasmid that would probably occur when transfected hepatocytes divide in vivo. Another reason was that PH prior to hepatocyte isolation is unlikely to be readily accepted should autologous hepatocyte implants become a clinical option in future.
We have previously reported that the bifunctional promoter consisting of the human metallothionein IIA promoter linked to a single ChoRE of the L-PK promoter responds to glucose and zinc. 12 In our studies of regulated insulin expression, promoter constructs with Diabetic C57BL/6J mice were implanted with B8 Â 10 5 viable transfected hepatocytes in regenerating liver. Glucose solution (75 mg/ml; 1.5 mg/g body weight) was administered to three mice as a single intravenous bolus 3 days after hepatocyte implantation, while two control mice received an identical volume of glucose-free saline. Blood was drawn for plasma insulin RIA just before, 10, 20 and 30 min after glucose or saline injection. Parentheses are % change, where + denotes increase and À denotes decrease in insulin concentrations after bolus saline or glucose injection compared to plasma insulin concentration before injection. Diabetic and nondiabetic C57BL/6J mice were implanted with B8 Â 10 5 viable transfected hepatocytes at the sites indicated. Glucose (1.5 mg/g body weight) was administered as a single intraperitoneal injection 5 days after hepatocyte implantation. Blood was drawn for plasma insulin RIA just before and 3 h after glucose challenge (n ¼ 3 for all groups). Data are mean7s.e.m. Parentheses are % change in plasma insulin levels. Controls were diabetic (n ¼ 3) and nondiabetic (n ¼ 3) mice implanted with transfected hepatocytes and injected with saline instead of glucose. Percentage change was -8% for control diabetic mice and À10% for control nondiabetic mice.
Hepatocyte-mediated therapy of murine diabetes NKF Chen et al tandem copies of ChoRE were not superior to constructs with a single copy of ChoRE (Lok SHL and Kon OL, unpublished data). Two mutations introduced into wildtype proinsulin cDNA to create tetrabasic furin recognition sites resulted in processing of at least 90% proinsulin to insulin by primary hepatocytes. Cleavage of modified proinsulin is likely to occur in the trans-Golgi network where furin is localized 13 and where transgenic insulin expressed in hepatocytes has been located. 14 A third modification was introduced because the HisB10Asp variant has four-to five-fold higher biological potency than native insulin, possibly due to higher avidity of receptor binding 15 and more rapid secretion via the constitutive pathway. 
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In b-cells, induction of proinsulin synthesis by acute exposure to glucose (p4 h) is achieved predominantly by increased translation, 17 while chronic glucose stimulation (412 h) also increases transcription and insulin mRNA stability. 18 In contrast, acute glucose induction of proinsulin synthesis and insulin secretion by primary hepatocytes in this study was at least partly transcriptional (Table 1 ) and secretory granules were not seen on electron microscopy (data not shown). Under these conditions, stimulated insulin secretion could be expected to have slower onset than secretion from storage granules of neuroendocrine cells. Our data show that the ChoRE was functional in vivo (Table 3) as basal serum insulin levels in all groups of diabetic mice implanted with transfected hepatocytes were higher compared to nondiabetic mice identically implanted. The uniformly lower basal serum insulin levels in nondiabetic mice were not, however, due to a lower capacity for transgene expression, since glucose challenge stimulated a proportionately high response ( Table 3 ). The mechanism of glucose-responsive transcription via the ChoRE of the L-PK promoter is mediated by a ChoRE-binding protein (ChREBP), which is highly expressed in liver. Nuclear translocation and DNA-binding activity of ChREBP is positively regulated by dephosphorylation of specific serine and threonine residues in a high-glucose environment, thereby upregulating transcription, while protein kinase A-catalyzed phosphorylation has the opposite effect. Changes in DNA-binding activity of ChREBP occur within 10 min in vivo. 19 The pattern of rapidly stimulated insulin secretion coupled to a slower decline that we observed by exposing primary hepatocytes to a timed glucose stimulus in vitro (Figure 2b ) was unexpected, but closely resembles the in vivo insulin response when normal human subjects are challenged with a glucose load. 20 Perifusing primary hepatocytes with zinc also rapidly and reversibly stimulated insulin secretion (Figure 2c ). These rapid responses in vitro were mirrored by comparably brisk increases in plasma human insulin when diabetic mice were stimulated with a single intravenous glucose injection in vivo (Table 2) . Our results differ from another study in which primary rat hepatocytes transduced with a different insulin transgene construct showed a significant increase in insulin secretion only 4 h after incubation in 27.5 mM glucose. 21 Although the reasons for these kinetic differences are unclear, it may be related to the known strength of the human metallothionein IIA promoter in driving expression of transgenes in liver. 22 High promoter strength is consistent with distinct cytoplasmic immunostaining for human insulin in hepatocytes electroporated with p3MTChins (Figure 4) , whereas rat hepatocytes transduced with a rat albumin promoter-insulin expression construct failed to show insulin immunostaining and also responded slowly to glucose stimulation. 21 It is possible that the combination of a strong promoter, faster transit through a constitutive secretory pathway of the HisB10Asp variant 16 used in this study and a putative rate-limiting step in the final stages of secretion by primary mouse hepatocytes resulted in substantial intracellular accumulation of presynthesized human insulin (Figure 4a-c) . Thus, transfected hepatocytes were poised to respond rapidly when extracellular concentrations of glucose (Figure 2b ) or zinc (Figure 2c) were raised.
While zinc is not a physiological regulator of insulin synthesis by b cells, it is a normal micronutrient. The ability of the bifunctional promoter to increase insulin secretion in response to glucose, zinc or both stimuli 12 provides a means of maintaining adequate basal interprandial insulin secretion, with the additional capacity of stimulating insulin secretion in response to post-prandial increase in blood glucose. The threshold concentrations of glucose and zinc that stimulated insulin secretion from transfected hepatocytes of 2.5 mM and between 10 and 15 mM, respectively (Figure 2a) , are physiological. Moreover, our data provide evidence that insulin-secretory capacity had not reached maximum even at the highest concentrations of glucose (25 mM) and zinc (60 mM) tested. The fact that hypoglycemia was never documented in any of the treated mice, even after overnight fasting, also indicates that basal expression of insulin from the bifunctional promoter was not excessive, and is consistent with quasi-physiological glucose-regulated transgene expression.
We chose to implant donor hepatocytes by direct interstitial injection into liver or mesentery because infusion of donor hepatocytes through the portal vein was associated with high mortality while the transit of donor hepatocytes to the recipient liver after intrasplenic implantation was inconsistent in our experience. Our data show that, although all three implantation sites were effective in correcting hyperglycemia acutely, implantation in regenerating liver produced the best outcome, as judged by survival (Figure 3a) , weight gain (Figure 3b ), higher plasma insulin levels ( Figure 3e and Table 3 ) and better glycemic control (Figure 3c ). It is probable that implanted hepatocytes engrafted better in partially resected liver because vasculogenesis and tissue remodelling that accompany liver regeneration favoured incorporation of donor hepatocytes in liver lobules. Implantation into regenerating liver resulted in the highest mean plasma insulin concentration after 24 h. This treatment group also maintained highest plasma human insulin concentrations throughout the period of observation compared to groups implanted in unresected liver (P ¼ 0.0006) or mesentery (Po0.0001) ( Figure  3e ). The steep decline after the first day was consistent with restoration of normoglycemia, but may also have reflected failure of some implanted hepatocytes to engraft.
Cognizant of the regenerative capacity of pancreatic islets, 23 we sought to exclude the possibility that recovery of euglycemia in STZ-diabetic mice (Figure 3c ) was unrelated to engraftment of insulin-secreting donor hepatocytes. Serial plasma levels of mouse C-peptide (Figure 3f ) showed no significant difference between the 4th and 30th days after STZ treatment, indicating negligible recovery of endogenous islet function.
Cytochemical staining of recipient livers for b-galactosidase activity showed that implanted donor cells were not restricted to the site of injection but had dispersed widely throughout the host liver (Figure 4a-c) . Immunohistochemical staining using an anti-human insulin antibody showed that donor cells preferentially engrafted around the central veins of liver lobules. These observations suggest that donor cells were conveyed in the liver microvasculature to their sites of engraftment and that host liver remodelling and donor hepatocyte migration during active regeneration determined the Glucose tolerance of all groups of treated diabetic mice was significantly better than control diabetic mice (Pp0.0001; Figure 3d ), but also significantly worse than non-diabetic mice (Pp0.0003), thus showing only partial metabolic correction by the implanted hepatocytes. Nonetheless, the fact that a majority of surviving treated mice maintained euglycemia for at least 77 days (data not shown) indicated stable retention of the plasmid transgene within implanted hepatocytes.
Other investigators have recently shown that liver is capable of glucose-responsive insulin secretion. 21, 24, 25 Our approach differs in not relying on virally mediated gene transfer, 21, 24 thus avoiding concerns of biosafety and immunogenicity. Moreover, modifying adult hepatocytes ex vivo enables insulin secretion to be verified before implantation in vivo. Yasutomi et al 25 also used a nonviral vector, but delivered the plasmid transgene by systemic high-volume and high-pressure intravascular administration, a technique that is likely to have serious adverse hemodynamic effects in human subjects. Furthermore, restoration of normoglycemia in their study was short-lived (less than 8 days) 25 in contrast to our results. Indeed, while all mock-implanted diabetic mice were dead by day 92, three of 19 hepatocyteimplanted diabetic were alive for more than 127 days and two remained normoglycemic (data not shown). Unlike stem cells, our strategy of modifying mature hepatocytes for quasi-physiological insulin secretion avoids the uncertain process of consistently and efficiently differentiating stem cells into b-like cells. Furthermore, while certain stem/progenitor cells may be tumorigenic in vivo, implanted primary adult hepatocytes are not. The strategy of achieving metabolic correction by ex vivo electroporation of somatic cells with a plasmid vector followed by in vivo implantation has been shown to be clinically effective in another metabolic disorder, that is, human factor VIII deficiency, using autologous fibroblasts. 26 In conclusion, we have developed cell-based diabetes treatment using syngeneic hepatocytes, that achieves sustained euglycemia in diabetic mice. It is possible that such an approach could be optimized for safe and effective autologous cell-based treatment of human diabetes in future.
Materials and methods
Materials
The following were from Sigma, USA: DMEM, RPMI-1640 medium, ethylene glycol-bis[b-aminoethyl ether]-N,N,N 0 ,N 0 -tetraacetic acid (EGTA), STZ and all reagents for ALT activity assay. Dulbecco's phosphate buffer and liver digest medium were from Invitrogen Life technologies, USA. The following suppliers in parenthesis were sources of: fetal calf serum (FCS) (Hyclone, USA); Percoll (Amersham Biosciences, Sweden); rat tail collagen I, collagen IV and Matrigel s dishes (Becton Dickinson, USA); reporter plasmids, pEGFP and pSEAP, and all reagents used for their assays (Becton Dickinson Biosciences Clontech, USA); plasmid preparation kits (Qiagen, Germany); radioimmunoassay (RIA) kits for human insulin, human proinsulin and mouse C-peptide (Linco Research, USA); Glucometer Elite XL and blood glucose test strips (Bayer, USA); Nucleofectort electroporation device and solutions (Amaxa GmbH, Germany). Histochemical staining was performed with b-Gal Staining Set (Roche Applied Science, Germany). Immunohistochemical analysis was performed using a prediluted monoclonal mouse anti-human insulin antibody (Zymed Laboratories, USA), Target Retrieval Solution pH 9.9 and ChemMatet Envisiont detection kit (Dako A/S, Denmark).
Plasmid construction
Human proinsulin cDNA sequence was modified to introduce furin cleavage sites at the B chain/C-peptide and C-peptide/A chain junctions by PCR-based mutagenesis (QuikChange s Site-Directed Mutagenesis protocol, Stratagene, USA) into pMTChins in which human proinsulin expression is driven by a 3 kb fragment of the human metallothionein IIA promoter linked to a single copy of the ChoRE. The following primers were used to convert the B chain/C-peptide junctional sequence from KTRR to RTRR: GGCTTCTTCTACACACCCAGGACCC GG (forward) and GCGGGTCCTGGGTGTGTAGAA GAAGCC (reverse). Primers that converted the Cpeptide/A chain junctional sequence from LQKR to RQKR were:
GAGGGGTCCCGGCAGAAGCGTGGCATTGTG (forward) and CACAATGCCACGCTTCTGCCGGGACCCC TC (reverse). A third modification effected the aminoacid substitution HisB10Asp using GGTGCGGCTCA GACCTGGTGGAAGCTC (forward) and GAGCTTC CACCAGGTCTGAGCCGCACAG (reverse). The resulting modified construct, p3MTChins, was used in all experiments.
Isolation of primary hepatocytes
We isolated primary hepatocytes from adult male C57BL/6J or Rosa26 mice as described by Bumgardner et al 27 with the following modifications. The liver was sequentially perfused in situ with 2.5 mM EGTA in calcium-free Dulbecco's phosphate buffer (3-4 ml/min for 7 min at 371C) and with liver digest medium under the same conditions for 13 min. A cellular fraction enriched in hepatocytes was obtained as a pellet after centrifugation (140 g, 15 min at 41C) on a discontinuous Percoll gradient (15-30-45-60%).
Gene transfer
Primary mouse hepatocytes were transfected using the Nucleofectort system. In all, 5-7 mg of endotoxin-free plasmid DNA was added to 1 Â 10 6 hepatocytes in 0.1 ml Nucleofectort solutions #3551 and #3541 mixed in equal ratio. Electroporation was performed using any one of the preset Amaxa programs. Immediately after electroporation, cells were transferred to matrix-coated (collagen I, collagen IV or Matrigel 
, where a is the C t value of the uninduced sample and x is the C t value of an induced sample, b and y are, respectively, the minus reverse transcriptase controls for a and x. Insulin and HPRT mRNA, and minus RT controls were measured in quadruplicate RT-PCR assays. Each assay was performed with duplicate reactions. hepatocytes electroporated with 5 mg p3MTChins and 3 mg pSEAP were cultured on 35 mm collagen I dishes 24 h before perifusion with high glucose or zinc medium, respectively. DMEM from a peristaltic pump (2 ml/min) was delivered in a constant stream over the entire surface of the culture dish, while the perfusate was collected through a small opening at the bottom of the dish located directly opposite the point of inflow. The perfusate was collected continuously in 2-min fractions from the start of the washout period (2.5 mM glucose for 30 min) until the end of each experiment. For glucose induction, hepatocytes were stimulated twice by 25 mM glucose (40 min each) separated by a 40-min period of 2.5 mM glucose. For zinc induction, two exposures to 60 mM zinc (30 min) were separated by 30 min of zinc-free perifusion. All perfusate fractions were assayed for human insulin, SEAP and ALT activity.
Radioimmunoassays
Human insulin, human proinsulin and mouse C-peptide in conditioned media or mouse plasma were quantitated by RIAs having the following specificities and performed to the supplier's protocols. Human insulin-specific RIA was o0.2% and 0.1% crossreactive with human proinsulin and rat insulin, respectively. The ultrasensitive human insulin RIA was 6% crossreactive with human proinsulin and o1% with rat insulin. Human proinsulin RIA was o0.1% crossreactive with human insulin and human C-peptide. The RIA for rat C-peptide was 100% crossreactive with mouse C-peptide, o0.1% with human C-peptide, o0.01% with human proinsulin and had no crossreactivity with human insulin.
Animal studies
All studies were performed on 6-8-week-old male C57BL/6J and Rosa26 mice exposed to 12-h cycles of light and dark at 18-241C. Unless otherwise specified, water and standard rodent chow were provided ad libitum.
Induction of diabetes. Diabetes was induced by four consecutive daily intraperitoneal injections of STZ (100 mg/kg body weight/day). Fasting blood glucose levels were determined on day 5 (1 day before hepatocyte implantation) using a glucometer and glucose test strips. Mice whose fasting blood glucose levels exceeded 14.4 mM were considered diabetic. Implantation of primary hepatocytes. 1 Â 10 6 freshly isolated hepatocytes were electroporated with 5 mg p3MTChins as described above. About 8 Â 10 5 viable electroporated cells in 0.1 ml Nucleofector solution were delivered by direct interstitial injection using a 29 G needle into the right lateral and right medial lobes of unresected liver, of partially hepatectomized liver or into the mesentery of diabetic mice under general anesthesia. Control diabetic mice were implanted with hepatocytes processed identically except for electroporation (mock implanted).
Serial monitoring of diabetic status. Heparinized blood (350 ml) was drawn from the retro-orbital plexus Hepatocyte-mediated therapy of murine diabetes NKF Chen et al on the first day of STZ administration, on the day of hepatocyte implantation, and thereafter 1, 3, 6, 10, 20 and 30 days after implantation. After centrifugation at 16 100 g and 41C for 15 min plasma samples were stored at À201C until assayed for human insulin and rat C-peptide. Blood glucose levels and body weights were also monitored on the same days. Exogenous insulin was never administered.
Glucose tolerance test. This was performed after an overnight fast on all diabetic mice (implanted with transfected or untransfected hepatocytes) and on control nondiabetic mice of the same age and sex. Glucose solution (75 mg/ml; 1.5 mg/g body weight) was injected intraperitoneally and blood glucose was measured at 0, 30, 60, 120 and 180 min using glucose test strips. Glucose tolerance was compared by calculating the AUC, which was the sum of the trapezoidal area under the blood glucose curve (to 180 min) after baseline values were subtracted.
Temporal response of glucose-induced insulin secretion in vivo. At 3 days after implantation of syngeneic primary hepatocytes transfected with p3MTChins, an intravenous bolus of glucose solution (75 mg/ml and 1.5 mg/g body weight) was administered to diabetic mice via the inferior vena cava. Blood was drawn for plasma insulin assay before and at intervals (10, 20 and 30 min) after glucose stimulation. In order to avoid possible artifacts caused by hypovolemia, the blood volume of each mouse was replaced with an equal volume of intravenous 0.9% NaCl after each blood sampling.
Immunohistochemistry
Fresh liver removed from C57BL/6 mice implanted with p3MTChins-transfected Rosa26 hepatocytes and from control nondiabetic mice implanted with untransfected hepatocytes were minced, fixed in 10% formalin for 15 min, and stained for b-galactosidase activity. Positively stained tissues were further fixed for 12 h and processed to 4 mm paraffin sections. After antigen retrieval (microwave heat in citrate buffer, pH 6.0), sections were incubated with monoclonal antibody against human insulin for 45 min. Bound primary antibody was detected with ChemMatet Envisiont detection kit using the supplier's protocol. Paraffin sections were counterstained with hematoxylin.
The following procedure was used to demonstrate colocalization of b-galactosidase activity and transgenic human insulin expression. Liver was minced, fixed in 0.5% glutaraldehyde for 20 min and washed thrice in 2 mM MgCl 2 , 0.01% (w/v) sodium deoxycholate, 0.02% (v/v) Nonidet P-40 and 100 mM sodium phosphate buffer, pH 8.0. Tissues were stained with X-Gal solution for 4 h (b-Gal Staining Set, Roche, Germany), washed thrice in phosphate-buffered saline and post-fixed in 10% formalin for 12 h. Tissue was manually processed according to a published protocol, 28 except that xylene was replaced by Histocleart (National Diagnostics, Inc., USA). Antigen retrieval on 4 mm sections was performed by microwave heating in Dako Target Retrieval Solution, pH 9.9. Antibody detection was as described above.
Statistical and survival analysis
Statistical significance was determined by Student's t-test. Survival data were presented by the Kaplan-Meier method using SPSS.
